Pfizer Corporation

Allergan, Inc.

Pfizer Products Inc.

Evgenyi Y Shalaev

Renuka Devi Reddy

Carl Bernard Ziegler

Ravi Mysore Shanker

George Joseph Quallich

Antone John deBettencourt, Iii

Peter Robert Rose

Maurice Abiad

Bhas Dani

Carl B Ziegler, Jr

Roger N Kimball

Jinping Wan

Ke Wu

Prem Swaroop Mohanty

Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.

Non-protein clostridial toxin compositions

Described herein is a solid complex comprising (Z)-7-((1R,2R,3R,5S)-2-((S,E)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide (hereinafter 'Compound 1') and &#x3b3;-cyclodextrin, and preparations and uses thereof. Also described herein are certain solid forms, preparations and uses thereof. 

Solid complex, preparations and uses thereof

Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.

Process for annealing amorphous atorvastatin

A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.

Process for forming amorphous atorvastatin

Formulations containing an antibacterial alkali metal salt of a cephalosporin compound and methods of treating bacterial infections in dogs and cats.

Methods of treatment and formulations of cephalosporin

The invention provides methods of protecting solid-state proteins from the effects of ionizing radiation which comprise combining the protein with a radiation-protecting amount of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde; radiation-protecting amounts of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; or radiation-protecting amounts of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde and isopropanol, prior to exposing the protein to ionizing radiation. The invention further provides radiation-resistant pharmaceutical formulations comprising a protein and a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde; a protein and a combination of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; or a protein and a combination of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde and isopropanol. The invention still further provides a composition comprising a combination of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, and for the use of such composition in pharmaceutical formulations as a radioprotectant.

Growing community of inventors

Old Lyme, CT, United States of America

Evgenyi Y Shalaev